The transmission of critical medical information is stuck in the past. Due to an outdated and unnecessary rule, pharmacies and healthcare providers still receive prescription drug information on paper, which is wasteful, harmful to the environment, and nonsensical. Legislation to update this process and bring common sense to the dissemination of this critical information has […]
Price controls in any industry do not work and inevitably lead to shortages and disrupted markets. Price controls on biopharmaceuticals are especially harmful because they raise costs, stifle research and development of new cures and treatments, and threaten America’s position as the global industry leader. As the Inflation Reduction Act (IRA) was being considered by […]
The 340B Drug Discount Program started in 1992 with the laudable intention of helping federally funded hospitals that serve a large number of uninsured patients cover the costs of drugs and provide discounts to patients. However, due to the lack of a clear definition of an eligible patient and poor oversight, the program has drifted […]
Eliminating waste, fraud, and abuse continues to be a priority across the legislative and executive branches of the federal government. Lawmakers who are fighting against wasteful spending should agree to eliminate an outdated and unnecessary rule that would result in the modernization of how critical medical information is transmitted. It would both bring common sense […]
Tobacco harm reduction (THR) products have been proven to be a safer alternative to cigarettes and an effective way to help smokers quit. On June 30, 2026, the Food and Drug Administration (FDA) took a significant step to increase the availability and use of THR products by announcing the approval of 20 Zyn nicotine pouch […]
The U.S. is the global leader in pharmaceutical research and development, and foreign countries have been taking advantage of this investment by not paying their fair share of those costs. On June 18, 2026, the Trump administration took a step in the right direction to resolve this problem when the United States Trade Representative (USTR) […]
As Americans prepare to celebrate the 250th anniversary of the nation’s founding, the festivities should include recognition of the United States as the global leader in biopharmaceutical development and innovation. However, America’s place atop the globe is being challenged by government intervention, specifically provisions in the Inflation Reduction Act (IRA) and Most Favored Nation (MFN) […]
On the eve of Memorial Day weekend, Tennessee Governor Bill Lee (R) signed SB 2040, the Freedom, Access, and Integrity in Registered Pharmacy (FAIR Rx) Act into law. He may have decided to act late on Friday, May 22, because the law will make healthcare less accessible and more expensive and cause dozens of businesses […]
The Food and Drug Administration (FDA) delivered a major victory by expanding the number of tobacco harm reduction (THR) products that smokers can access to transition away from cigarettes. On May 5, 2026, the FDA issued its first marketing authorization of fruit-flavored electronic cigarette products, which overturns the 2020 ban on such products. The FDA […]
As the rising cost of healthcare continues to concern American businesses and families, the House Ways and Means Committee has been holding a series of hearings exploring the variety of causes of rising healthcare costs. The April 28, 2026, hearing with health system CEOs examined the role of health systems in relation to healthcare affordability, […]
